Medincell Achieves Major Milestone with U.S. FDA Approval of WELTRUZA™ (olanzapine)

Medincell's partner Teva Pharmaceuticals received U.S. FDA approval for WELTRUZA™, the first once-monthly subcutaneous long-acting injectable olanzapine for schizophrenia, expanding Medincell's long-acting injectable technology portfolio.

This Wire brief sits within Fusion42's coverage of Health, and 14 sources have reported it between 9 Oct 2026 and 10 Oct 2026.